Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment source : Jaguarhealth.gcs-web.com save search
Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Published: 2023-09-13 (Crawled : 12:30) - jaguarhealth.gcs-web.com
JAGX | News | $0.168 -6.62% -6.39% 38M
|
Health Technology
|
| O: -0.71%
H: 3.71%
C: -6.39%
patent japan health treatment
Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
Published: 2023-08-17 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | News | $0.168 -6.62% -6.39% 38M
|
Health Technology
|
| O: -4.06%
H: 0.41%
C: -2.97%
diarrhea health cancer treatment family crofelemer trial
Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
Published: 2023-08-16 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | News | $0.168 -6.62% -6.39% 38M
|
Health Technology
|
| O: 6.57%
H: 0.0%
C: 0.0%
diarrhea indicate world sclerosis treatment pharmaceuticals potential
Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
Published: 2023-08-08 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.168 -6.62% -6.39% 38M
|
Health Technology
|
| O: -0.66%
H: 0.0%
C: 0.0%
fda drug disease health microvillus treatment application crofelemer
Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome (SBS)
Published: 2023-08-01 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.168 -6.62% -6.39% 38M
|
Health Technology
|
| O: 1.02%
H: 0.67%
C: -2.84%
fda drug diarrhea health treatment application crofelemer
Jaguar Health Names Principal Investigators for Clinical Trial to Support Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2023-07-26 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | News | $0.168 -6.62% -6.39% 38M
|
Health Technology
|
| O: 2.57%
H: 11.58%
C: 6.27%
diarrhea health approval treatment trial
Jaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar’s 2023 Focus on Human Drug Development
Published: 2023-02-01 (Crawled : 15:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.168 -6.62% -6.39% 38M
|
Health Technology
|
| O: 3.97%
H: 1.7%
C: -3.61%
treatment drug diarrhea health commercialization license agreement china
Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
Published: 2022-10-26 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.168 -6.62% -6.39% 38M
|
Health Technology
|
| O: -0.35%
H: 2.85%
C: 2.56%
treatment research diarrhea breast health crofelemer cancer publication study
Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation by FDA of Investigational New Drug (IND) Application for NP-300, a Novel Drug Candidate for the Symptomatic Relief and Treatment of Diarrhea from Cholera and Other Pathogens
Published: 2022-09-29 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.168 -6.62% -6.39% 38M
|
Health Technology
|
| O: 5.29%
H: 2.79%
C: -10.22%
np-300 treatment fda pharmaceuticals drug candidate diarrhea health application pathogens
Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China
Published: 2022-06-29 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.168 -6.62% -6.39% 38M
|
Health Technology
|
| O: 6.83%
H: 10.61%
C: -3.06%
treatment diarrhea health commercialization license crofelemer agreement china
Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2022-04-27 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | News | $0.168 -6.62% -6.39% 38M
|
Health Technology
|
| O: 1.12%
H: 6.67%
C: 5.8%
treatment drug diarrhea health
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, March 6th, During the Western Veterinary Conference (WVC) in Las Vegas
Published: 2022-03-01 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | News | $0.168 -6.62% -6.39% 38M
|
Health Technology
|
| O: 2.72%
H: 10.71%
C: 0.45%
veterinarians day treatment health conference diarrhea therapy
Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs
Published: 2022-02-16 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | News | $0.168 -6.62% -6.39% 38M
|
Health Technology
|
| O: -0.76%
H: 1.54%
C: -3.29%
treatment fda health diarrhea crofelemer designation
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, January 16th During the Veterinary Meeting & Expo (VMX) Conference in Orlando, Florida
Published: 2022-01-12 (Crawled : 16:20) - jaguarhealth.gcs-web.com
FNCTF | News | $11.16 1.13% -20.84% 31
|
Communications
|
| O: 0.0%
H: 0.0%
C: 0.0%
JAGX | News | $0.168 -6.62% -6.39% 38M
|
Health Technology
|
| O: 12.9%
H: 0.0%
C: 0.0%
veterinarians treatment health conference diarrhea therapy
Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA
Published: 2021-12-21 (Crawled : 20:20) - jaguarhealth.gcs-web.com
JAGX | News | $0.168 -6.62% -6.39% 38M
|
Health Technology
|
| O: -7.25%
H: 3.91%
C: -7.81%
treatment fda health approval diarrhea therapy crofelemer
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.